Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir

AIDS

Volumn 11, Issue 12, 1997, Pages

  Lorenzi, Patrizio ^a   Yerly, Sabine ^b   Abderrakim, Karmine ^c   Fathi, Marc ^c   Rutschmann, Olivier T ^a   Von Overbeck, Jan ^d   Leduc, Dominique ^e   Perrin, Luc ^b   Hirschel, Bernard ^a,f  

^a Kantonsspital Aarau   (Switzerland)

^b Laboratory of Virology

^c UNIVERSITY HOSPITAL   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e CENTRE HOSPITALIER   (France)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

AIDS; Protease mutations; Ritonavir; Saquinavir

Indexed keywords

ANTIVIRUS AGENT; RITONAVIR; SAQUINAVIR;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPERTRIGLYCERIDEMIA; INGESTION; LIVER DISEASE; MALE; MULTICENTER STUDY; PARESTHESIA; PRIORITY JOURNAL; VIREMIA;

EID: 0030792728     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199712000-00002     Document Type: Article

References (13)

1. Merry C, Barry MC, Mulcahy F, et al.: Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997, 11:F29-F33.
2. Cameron W, Sun E, Markowitz M, et al.: Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data. XI International Conference on AIDS. Vancouver, July 1996 (abstract ThB934].
3. Condra JH, Schleif WA, Blahy OM, et al: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:117-122.
4. Ledergerber B, von Overbeck J, Egger M, et al.: The Swiss HIV Cohort Study: rationale, organization, and selected baseline characteristics. Soz Präventivmed 1994, 39:387-394.
5. Lech WJ, Wang G, Yang YL, et al.: In vivo sequence diversity of the protease of human immunodeficiency virus type T : presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996, 70:2038-2043.
6. Chen X, Wijsbeck J, Van Veen J, et al.: Solid-phase extraction for the screening of acidic, neutral and basic drugs in plasma using a single column procedure on Bond Elut certify. J Chromatogr 1990, 529:161-166.
7. Degel F: Comparison of new solid-phase extraction methods for Chromatographic identification of drugs in clinical toxicological analysis. Clin Biochem 1996, 29:529-540.
8. Grupta RN: Column liquid Chromatographic determination of clozapine and N-desmethylclozapine in human serum using solid-phase extraction. J Chromatogr 1995, 673:311-315.
9. Centers for Disease Control: 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41 (RR-17) 11-19.
10. Kozal MJ, Shah N, Shen N, et al.: Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Med 1996, 2:760-766.
11. Jacobsen H, Hänggi M, Ott M, et al.: In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis 1996, 173:1379-1387.
12. Eberle J, Bechowsky B, Rose D, et al.: Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res Hum Refroviruses 1995, 11:671-676.
13. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.